Video

Aurion Biotech: Treating endothelial disease with one donor

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|ASCRS

Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Edward Holland, MD, chief medical advisor for Aurion Biotech, discusses the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
(Image credit: AdobeStock/Vitalii Vodolazskyi) Yale researchers identify corneal ulcer pathogens by testing tears
July 1st 2025

Yale researchers identify corneal ulcer pathogens by testing tears

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DR
June 28th 2025

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DR

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)
June 27th 2025

Kodiak Sciences to present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS)

Krystal Biotech doses first patient in phase 3 trial IOLITE
June 27th 2025

Krystal Biotech doses first patient in phase 3 trial IOLITE

© 2025 MJH Life Sciences

All rights reserved.